QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

The Journal of Neuroscience, November 16, 2005, 25(46):10598-10606; doi:10.1523/JNEUROSCI.2990-05.2005

This Article Full Text Full Text (PDF) Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (47) Citing Articles via Google Scholar Google Scholar Articles by Klunk, W. E. Articles by Mathis, C. A. Search for Related Content PubMed PubMed Citation Articles by Klunk, W. E. Articles by Mathis, C. A.

 Previous Article  |  Next Article 

Cellular/Molecular
Binding of the Positron Emission Tomography Tracer Pittsburgh Compound-B Reflects the Amount of Amyloid- in Alzheimer's Disease Brain But Not in Transgenic Mouse Brain

William E. Klunk,¹ Brian J. Lopresti,² Milos D. Ikonomovic,³ Iliya M. Lefterov,⁴ Radosveta P. Koldamova,⁵ Eric E. Abrahamson,³ Manik L. Debnath,¹ Daniel P. Holt,² Guo-feng Huang,² Li Shao,¹ Steven T. DeKosky,³ Julie C. Price,² and Chester A. Mathis²

Departments of ¹Psychiatry, ²Radiology, ³Neurology, ⁴Environmental and Occupational Health, and ⁵Pharmacology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213

During the development of in vivo amyloid imaging agents, an effort was made to use micro-positron emission tomography (PET) imaging in the presenilin-1 (PS1)/amyloid precursor protein (APP) transgenic mouse model of CNS amyloid deposition to screen new compounds and further study Pittsburgh Compound-B (PIB), a PET tracer that has been shown to be retained well in amyloid-containing areas of Alzheimer's disease (AD) brain. Unexpectedly, we saw no significant retention of PIB in this model even at 12 months of age when amyloid deposition in the PS1/APP mouse typically exceeds that seen in AD. This study describes a series of ex vivo and postmortem in vitro studies designed to explain this low retention. Ex vivo brain pharmacokinetic studies confirmed the low in vivo PIB retention observed in micro-PET experiments. In vitro binding studies showed that PS1/APP brain tissue contained less than one high-affinity (K_d = 1-2 nM) PIB binding site per 1000 molecules of amyloid- (A), whereas AD brain contained >500 PIB binding sites per 1000 molecules of A. Synthetic A closely resembled PS1/APP brain in having less than one high-affinity PIB binding site per 1000 molecules of A, although the characteristics of the few high-affinity PIB binding sites found on synthetic A were very similar to those found in AD brain. We hypothesize that differences in the time course of deposition or tissue factors present during deposition lead to differences in secondary structure between A deposited in AD brain and either synthetic A or A deposited in PS1/APP brain.

Key words: transgenic mouse; amyloid-; plaques; neuroimaging; positron emission tomography; benzothiazole

---

Received July 20, 2005; revised September 23, 2005; accepted October 3, 2005.

This article has been cited by other articles:

				W. E. Klunk Biopsy Support for the Validity of Pittsburgh Compound B Positron Emission Tomography With a Twist Arch Neurol, October 1, 2008; 65(10): 1281 - 1283. [Full Text] [PDF]

				M. D. Ikonomovic, W. E. Klunk, E. E. Abrahamson, C. A. Mathis, J. C. Price, N. D. Tsopelas, B. J. Lopresti, S. Ziolko, W. Bi, W. R. Paljug, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease Brain, June 1, 2008; 131(6): 1630 - 1645. [Abstract] [Full Text] [PDF]

				J. Maeda, B. Ji, T. Irie, T. Tomiyama, M. Maruyama, T. Okauchi, M. Staufenbiel, N. Iwata, M. Ono, T. C. Saido, et al. Longitudinal, Quantitative Assessment of Amyloid, Neuroinflammation, and Anti-Amyloid Treatment in a Living Mouse Model of Alzheimer's Disease Enabled by Positron Emission Tomography J. Neurosci., October 10, 2007; 27(41): 10957 - 10968. [Abstract] [Full Text] [PDF]

				A. Lockhart, J.R. Lamb, T. Osredkar, L.I. Sue, J.N. Joyce, L. Ye, V. Libri, D. Leppert, and T.G. Beach PIB is a non-specific imaging marker of amyloid-beta (A{beta}) peptide-related cerebral amyloidosis Brain, October 1, 2007; 130(10): 2607 - 2615. [Abstract] [Full Text] [PDF]

				M. T. Fodero-Tavoletti, D. P. Smith, C. A. McLean, P. A. Adlard, K. J. Barnham, L. E. Foster, L. Leone, K. Perez, M. Cortes, J. G. Culvenor, et al. In Vitro Characterization of Pittsburgh Compound-B Binding to Lewy Bodies J. Neurosci., September 26, 2007; 27(39): 10365 - 10371. [Abstract] [Full Text] [PDF]

				N. Nelissen, M. Vandenbulcke, K. Fannes, A. Verbruggen, R. Peeters, P. Dupont, K. Van Laere, G. Bormans, and R. Vandenberghe A{beta} amyloid deposition in the language system and how the brain responds Brain, August 1, 2007; 130(8): 2055 - 2069. [Abstract] [Full Text] [PDF]

				W. E. Klunk, J. C. Price, C. A. Mathis, N. D. Tsopelas, B. J. Lopresti, S. K. Ziolko, W. Bi, J. A. Hoge, A. D. Cohen, M. D. Ikonomovic, et al. Amyloid Deposition Begins in the Striatum of Presenilin-1 Mutation Carriers from Two Unrelated Pedigrees J. Neurosci., June 6, 2007; 27(23): 6174 - 6184. [Abstract] [Full Text] [PDF]

				D. M. Holtzman Pittsburgh Compound B Retention and Verification of Amyloid Deposition Arch Neurol, March 1, 2007; 64(3): 315 - 316. [Full Text] [PDF]

				C. R. Jack Jr, M. Marjanska, T. M. Wengenack, D. A. Reyes, G. L. Curran, J. Lin, G. M. Preboske, J. F. Poduslo, and M. Garwood Magnetic Resonance Imaging of Alzheimer's Pathology in the Brains of Living Transgenic Mice: A New Tool in Alzheimer's Disease Research Neuroscientist, February 1, 2007; 13(1): 38 - 48. [Abstract] [PDF]

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help